 | • レポートコード：MRC2-11QY11116 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は膀胱がん治療・診断のグローバル市場について調査・分析したレポートです。種類別（化学療法、免疫療法、放射線療法、その他）市場規模、用途別（病院、腫瘍治療センター、外来手術センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別膀胱がん治療・診断の競争状況、市場シェア ・世界の膀胱がん治療・診断市場：種類別市場規模 2015年-2020年（化学療法、免疫療法、放射線療法、その他） ・世界の膀胱がん治療・診断市場：種類別市場規模予測 2021年-2026年（化学療法、免疫療法、放射線療法、その他） ・世界の膀胱がん治療・診断市場：用途別市場規模 2015年-2020年（病院、腫瘍治療センター、外来手術センター、その他） ・世界の膀胱がん治療・診断市場：用途別市場規模予測 2021年-2026年（病院、腫瘍治療センター、外来手術センター、その他） ・北米の膀胱がん治療・診断市場分析：米国、カナダ ・ヨーロッパの膀胱がん治療・診断市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの膀胱がん治療・診断市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の膀胱がん治療・診断市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの膀胱がん治療・診断市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、GlaxoSmithKline、Merck、Novartis、Bristol-Myers Squibb、Eli Lilly、Roche、Sanofi、AstraZeneca、Celgene Corporation ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.
Based on the data from International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. Historically, bladder cancer has been associated with low patient awareness. Smoking has a high correlation with bladder cancer and this association is mostly unknown to the general public. But, in recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developed nations.
Market Analysis and Insights: Global Bladder Cancer Therapeutics and Diagnostics Market
The global Bladder Cancer Therapeutics and Diagnostics market size is projected to reach US$ 446.4 million by 2026, from US$ 415.6 million in 2020, at a CAGR of 6.9%% during 2021-2026.
Global Bladder Cancer Therapeutics and Diagnostics Scope and Market Size
Bladder Cancer Therapeutics and Diagnostics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Bladder Cancer Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
GlaxoSmithKline
Merck
Novartis
Bristol-Myers Squibb
Eli Lilly
Roche
Sanofi
AstraZeneca
Celgene Corporation
Market segment by Type, the product can be split into
Chemotherapy
Immunotherapy
Radiation Therapy
Others
Market segment by Application, split into
Hospitals
Oncology Treatment Centers
Ambulatory Surgery Centers
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Bladder Cancer Therapeutics and Diagnostics Revenue
1.4 Market by Type
1.4.1 Global Bladder Cancer Therapeutics and Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Immunotherapy
1.4.4 Radiation Therapy
1.4.5 Others
1.5 Market by Application
1.5.1 Global Bladder Cancer Therapeutics and Diagnostics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Oncology Treatment Centers
1.5.4 Ambulatory Surgery Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Bladder Cancer Therapeutics and Diagnostics Market Perspective (2015-2026)
2.2 Global Bladder Cancer Therapeutics and Diagnostics Growth Trends by Regions
2.2.1 Bladder Cancer Therapeutics and Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Bladder Cancer Therapeutics and Diagnostics Historic Market Share by Regions (2015-2020)
2.2.3 Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Bladder Cancer Therapeutics and Diagnostics Market Growth Strategy
2.3.6 Primary Interviews with Key Bladder Cancer Therapeutics and Diagnostics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Bladder Cancer Therapeutics and Diagnostics Players by Market Size
3.1.1 Global Top Bladder Cancer Therapeutics and Diagnostics Players by Revenue (2015-2020)
3.1.2 Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Players (2015-2020)
3.1.3 Global Bladder Cancer Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Bladder Cancer Therapeutics and Diagnostics Market Concentration Ratio
3.2.1 Global Bladder Cancer Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Bladder Cancer Therapeutics and Diagnostics Revenue in 2019
3.3 Bladder Cancer Therapeutics and Diagnostics Key Players Head office and Area Served
3.4 Key Players Bladder Cancer Therapeutics and Diagnostics Product Solution and Service
3.5 Date of Enter into Bladder Cancer Therapeutics and Diagnostics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Bladder Cancer Therapeutics and Diagnostics Historic Market Size by Type (2015-2020)
4.2 Global Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)
5.2 Global Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Bladder Cancer Therapeutics and Diagnostics Market Size (2015-2020)
6.2 Bladder Cancer Therapeutics and Diagnostics Key Players in North America (2019-2020)
6.3 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020)
6.4 North America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Bladder Cancer Therapeutics and Diagnostics Market Size (2015-2020)
7.2 Bladder Cancer Therapeutics and Diagnostics Key Players in Europe (2019-2020)
7.3 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020)
7.4 Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)
8 China
8.1 China Bladder Cancer Therapeutics and Diagnostics Market Size (2015-2020)
8.2 Bladder Cancer Therapeutics and Diagnostics Key Players in China (2019-2020)
8.3 China Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020)
8.4 China Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Bladder Cancer Therapeutics and Diagnostics Market Size (2015-2020)
9.2 Bladder Cancer Therapeutics and Diagnostics Key Players in Japan (2019-2020)
9.3 Japan Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020)
9.4 Japan Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Size (2015-2020)
10.2 Bladder Cancer Therapeutics and Diagnostics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020)
10.4 Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)
11 India
11.1 India Bladder Cancer Therapeutics and Diagnostics Market Size (2015-2020)
11.2 Bladder Cancer Therapeutics and Diagnostics Key Players in India (2019-2020)
11.3 India Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020)
11.4 India Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Bladder Cancer Therapeutics and Diagnostics Market Size (2015-2020)
12.2 Bladder Cancer Therapeutics and Diagnostics Key Players in Central & South America (2019-2020)
12.3 Central & South America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020)
12.4 Central & South America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Bladder Cancer Therapeutics and Diagnostics Introduction
13.1.4 Pfizer Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Details
13.2.2 GlaxoSmithKline Business Overview
13.2.3 GlaxoSmithKline Bladder Cancer Therapeutics and Diagnostics Introduction
13.2.4 GlaxoSmithKline Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020)
13.2.5 GlaxoSmithKline Recent Development
13.3 Merck
13.3.1 Merck Company Details
13.3.2 Merck Business Overview
13.3.3 Merck Bladder Cancer Therapeutics and Diagnostics Introduction
13.3.4 Merck Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020)
13.3.5 Merck Recent Development
13.4 Novartis
13.4.1 Novartis Company Details
13.4.2 Novartis Business Overview
13.4.3 Novartis Bladder Cancer Therapeutics and Diagnostics Introduction
13.4.4 Novartis Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020)
13.4.5 Novartis Recent Development
13.5 Bristol-Myers Squibb
13.5.1 Bristol-Myers Squibb Company Details
13.5.2 Bristol-Myers Squibb Business Overview
13.5.3 Bristol-Myers Squibb Bladder Cancer Therapeutics and Diagnostics Introduction
13.5.4 Bristol-Myers Squibb Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020)
13.5.5 Bristol-Myers Squibb Recent Development
13.6 Eli Lilly
13.6.1 Eli Lilly Company Details
13.6.2 Eli Lilly Business Overview
13.6.3 Eli Lilly Bladder Cancer Therapeutics and Diagnostics Introduction
13.6.4 Eli Lilly Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020)
13.6.5 Eli Lilly Recent Development
13.7 Roche
13.7.1 Roche Company Details
13.7.2 Roche Business Overview
13.7.3 Roche Bladder Cancer Therapeutics and Diagnostics Introduction
13.7.4 Roche Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020)
13.7.5 Roche Recent Development
13.8 Sanofi
13.8.1 Sanofi Company Details
13.8.2 Sanofi Business Overview
13.8.3 Sanofi Bladder Cancer Therapeutics and Diagnostics Introduction
13.8.4 Sanofi Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020)
13.8.5 Sanofi Recent Development
13.9 AstraZeneca
13.9.1 AstraZeneca Company Details
13.9.2 AstraZeneca Business Overview
13.9.3 AstraZeneca Bladder Cancer Therapeutics and Diagnostics Introduction
13.9.4 AstraZeneca Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020)
13.9.5 AstraZeneca Recent Development
13.10 Celgene Corporation
13.10.1 Celgene Corporation Company Details
13.10.2 Celgene Corporation Business Overview
13.10.3 Celgene Corporation Bladder Cancer Therapeutics and Diagnostics Introduction
13.10.4 Celgene Corporation Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020)
13.10.5 Celgene Corporation Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Bladder Cancer Therapeutics and Diagnostics Key Market Segments
Table 2. Key Players Covered: Ranking by Bladder Cancer Therapeutics and Diagnostics Revenue
Table 3. Ranking of Global Top Bladder Cancer Therapeutics and Diagnostics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Bladder Cancer Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Immunotherapy
Table 7. Key Players of Radiation Therapy
Table 8. Key Players of Others
Table 9. Global Bladder Cancer Therapeutics and Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Bladder Cancer Therapeutics and Diagnostics Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Bladder Cancer Therapeutics and Diagnostics Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Regions (2015-2020)
Table 13. Global Bladder Cancer Therapeutics and Diagnostics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Bladder Cancer Therapeutics and Diagnostics Market Growth Strategy
Table 19. Main Points Interviewed from Key Bladder Cancer Therapeutics and Diagnostics Players
Table 20. Global Bladder Cancer Therapeutics and Diagnostics Revenue by Players (2015-2020) (Million US$)
Table 21. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Players (2015-2020)
Table 22. Global Top Bladder Cancer Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bladder Cancer Therapeutics and Diagnostics as of 2019)
Table 23. Global Bladder Cancer Therapeutics and Diagnostics by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Bladder Cancer Therapeutics and Diagnostics Product Solution and Service
Table 26. Date of Enter into Bladder Cancer Therapeutics and Diagnostics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 29. Global Bladder Cancer Therapeutics and Diagnostics Market Size Share by Type (2015-2020)
Table 30. Global Bladder Cancer Therapeutics and Diagnostics Revenue Market Share by Type (2021-2026)
Table 31. Global Bladder Cancer Therapeutics and Diagnostics Market Size Share by Application (2015-2020)
Table 32. Global Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 33. Global Bladder Cancer Therapeutics and Diagnostics Market Size Share by Application (2021-2026)
Table 34. North America Key Players Bladder Cancer Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Bladder Cancer Therapeutics and Diagnostics Market Share (2019-2020)
Table 36. North America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 37. North America Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 38. North America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 39. North America Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 40. Europe Key Players Bladder Cancer Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Bladder Cancer Therapeutics and Diagnostics Market Share (2019-2020)
Table 42. Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 44. Europe Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 46. China Key Players Bladder Cancer Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 47. China Key Players Bladder Cancer Therapeutics and Diagnostics Market Share (2019-2020)
Table 48. China Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 49. China Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 50. China Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 51. China Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 52. Japan Key Players Bladder Cancer Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Bladder Cancer Therapeutics and Diagnostics Market Share (2019-2020)
Table 54. Japan Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 56. Japan Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Bladder Cancer Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Bladder Cancer Therapeutics and Diagnostics Market Share (2019-2020)
Table 60. Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 62. Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 64. India Key Players Bladder Cancer Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 65. India Key Players Bladder Cancer Therapeutics and Diagnostics Market Share (2019-2020)
Table 66. India Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 67. India Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 68. India Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 69. India Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Bladder Cancer Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Bladder Cancer Therapeutics and Diagnostics Market Share (2019-2020)
Table 72. Central & South America Bladder Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Bladder Cancer Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 74. Central & South America Bladder Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Bladder Cancer Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Product
Table 79. Pfizer Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 80. Pfizer Recent Development
Table 81. GlaxoSmithKline Company Details
Table 82. GlaxoSmithKline Business Overview
Table 83. GlaxoSmithKline Product
Table 84. GlaxoSmithKline Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 85. GlaxoSmithKline Recent Development
Table 86. Merck Company Details
Table 87. Merck Business Overview
Table 88. Merck Product
Table 89. Merck Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 90. Merck Recent Development
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Product
Table 94. Novartis Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 95. Novartis Recent Development
Table 96. Bristol-Myers Squibb Company Details
Table 97. Bristol-Myers Squibb Business Overview
Table 98. Bristol-Myers Squibb Product
Table 99. Bristol-Myers Squibb Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 100. Bristol-Myers Squibb Recent Development
Table 101. Eli Lilly Company Details
Table 102. Eli Lilly Business Overview
Table 103. Eli Lilly Product
Table 104. Eli Lilly Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 105. Eli Lilly Recent Development
Table 106. Roche Company Details
Table 107. Roche Business Overview
Table 108. Roche Product
Table 109. Roche Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 110. Roche Recent Development
Table 111. Sanofi Business Overview
Table 112. Sanofi Product
Table 113. Sanofi Company Details
Table 114. Sanofi Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 115. Sanofi Recent Development
Table 116. AstraZeneca Company Details
Table 117. AstraZeneca Business Overview
Table 118. AstraZeneca Product
Table 119. AstraZeneca Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 120. AstraZeneca Recent Development
Table 121. Celgene Corporation Company Details
Table 122. Celgene Corporation Business Overview
Table 123. Celgene Corporation Product
Table 124. Celgene Corporation Revenue in Bladder Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 125. Celgene Corporation Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Immunotherapy Features
Figure 4. Radiation Therapy Features
Figure 5. Others Features
Figure 6. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Oncology Treatment Centers Case Studies
Figure 9. Ambulatory Surgery Centers Case Studies
Figure 10. Others Case Studies
Figure 11. Bladder Cancer Therapeutics and Diagnostics Report Years Considered
Figure 12. Global Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Regions: 2020 VS 2026
Figure 14. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Bladder Cancer Therapeutics and Diagnostics Market Share by Players in 2019
Figure 17. Global Top Bladder Cancer Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bladder Cancer Therapeutics and Diagnostics as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Bladder Cancer Therapeutics and Diagnostics Revenue in 2019
Figure 19. North America Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Bladder Cancer Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
過活動膀胱治療薬の世界市場（～2026年） Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). North America is the largest consumption market of Overactive …- 大腸がん診断・治療の世界市場（～2026年） Colorectal cancer is the development of cancer from the colonor rectum. The main market drivers are increasing cancer prevention initiatives, technological advancements in radiology and chemotherapy, and increasing incidence and prevalence of colorectal cancer. Market Analysis and Insights: Global C…
- 膀胱がん治療薬の世界市場（～2026年） Bladder cancer refers to the growth of abnormal tissues in the lining of the bladder. These abnormal tissues are referred to as tumor, which even spread in the surrounding tissues or muscles. The increase in prevalence of bladder cancer, advanced health care services, technological advancements, dr…
- 膵臓がん治療薬の世界市場（～2026年） Pancreatic cancer therapy is recommended by clinicians for early detection of cancer. Pancreatic cancer generally diagnosed at a later stage, since the symptoms are not easily detected or diagnosed. Factors such as, chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity …
- 子宮頸がん診断検査の世界市場（～2026年） Market Analysis and Insights: Global Cervical Cancer Diagnostic Test Market The global Cervical Cancer Diagnostic Test market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data i…